Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04807166
Other study ID # JiangsuCHENG001
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2021
Est. completion date December 1, 2024

Study information

Verified date March 2021
Source The First Affiliated Hospital with Nanjing Medical University
Contact Wenjun Cheng, MD,PhD
Phone +86 13912996970
Email chengwenjundoc@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits. Therefore, this study is expected to investigate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer.


Description:

This study is a single-arm, multicenter, exploratory phase II study to observe the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer. The primary end point are progression free survival; the secondary end points include objective response rate, disease control rate, overall survival and safety. The subjects in this study: patients with newly diagnosed advanced (FIGO stage III-IV) ovarian cancer, including histologically or pathologically confirmed high-grade serous ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 56
Est. completion date December 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects must be female =18 years old; 2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1; 3. Postoperative administration time: within 12 weeks after the maximum tumor reduction operation; 4. Histologically or pathologically confirmed advanced (FIGO stage III - IV) ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; 5. Subjects have enough organ function: (1) Blood routine(without blood transfusion or hematopoietic stimulating factor within 7 days before screening ): a.Hemoglobin (HB)=9.0g/L; b.Absolute value of neutrophil (ANC)=1.5 * 10^9 / L; c.Platelet (PLT)=80 * 10^9 / L; (2) Liver and Renal function(without blood or albumin transfusion within 7 days before screening ): a. Alanine aminotransferase (ALT) and AST=2.5 times the upper limit of normal value and ALT (AST=5 times the upper limit of normal value when liver/bone metastasis) b. total bilirubin =1.5 times the upper limit of normal value; c.serum creatinine =1.5 times the upper limit of normal value, creatinine clearance=60 ml/min; (3)Blood coagulation function: a.Activated partial thromboplastin time, international standardized ratio adn prothrombin time =1.5 times the upper limit of normal value; b.Doppler echocardiographic evaluation: left ventricular ejection fraction(LVEF)= 50% 6. Subjects agreed to join the study and signed informed consent; Exclusion Criteria: 1. Previously received anti angiogenic drugs including but not limited to small molecules such as anotinib and apatinib and large molecules such as bevacizumab. 2. Patients allergic to the any test drug. 3. Combined disease/ history: 1. Clinical significant hemoptysis occurred within 3 months before admission (daily hemoptysis was greater than 50ml), or significant clinical bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis, etc; 2. Arteriovenous thrombosis events occurred within 6 months before grouping, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except venous thrombosis caused by venous catheterization due to early chemotherapy) and pulmonary embolism; 3. Hypertension, which can not be well controlled by antihypertensive drugs (systolic blood pressure>140 mmHg or diastolic blood pressure>90 mmHg); Myocardial infarction, severe / unstable angina pectoris, cardiac insufficiency above New York Heart Association(NYHA) , supraventricular or ventricular arrhythmias with clinical significance, and symptomatic congestive heart failure occurred within 6 months before grouping; 4. Interstitial lung disease, non-infectious pneumonia or uncontrollable systemic diseases (e.g. diabetes, pulmonary fibrosis and acute pneumonia); 5. Renal insufficiency: urine routine indicates urinary protein = + +, or confirms 24-hour urinary protein = 1.0g; 6. History of live attenuated vaccine vaccination within 28 days before the first study medication or expected live attenuated vaccination during the study period; 7. Human immunodeficiency virus infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis; 8. There were severe infections within 4 weeks before the first administration, including, but not limited to, bacteremia and severe pneumonia requiring hospitalization; active infections requiring systemic antibiotics treatment of grade CTCAE = 2 within 2 weeks before the first administration, or unexplained fever > 38.5 °C during the screening period / before the first administration (the researchers judged that fever caused by tumors could be included in the group); there was evidence of active tuberculosis infection within 1 year before administration; 9. Any other malignant tumor has been diagnosed within 3 years before enrollment, except for fully treated basal cell carcinoma or squamous cell skin cancer or cervical carcinoma in situ; 10. Major surgery was performed within 28 days before enrollment (tissue biopsy required for diagnosis and central venous catheterization via peripheral venipuncture are allowed); 11. Subjects who have previously received or are prepared to receive allogeneic bone marrow transplantation or solid organ transplantation; 12. Patients with peripheral neuropathy =2 grade 2; patients with active brain metastasis, carcinomatous meningitis, spinal cord compression, or diseases found in brain or leptomeninges by imaging CT or MRI examination during screening (patients with brain metastasis who had completed treatment 14 days before admission and whose symptoms were stable can be enrolled in the group, but no symptoms of cerebral hemorrhage should be confirmed by cranial MRI, CT or venography); 13. Factors that significantly affect the absorption of oral drugs, such as inability to swallow, chronic diarrhea, and intestinal obstruction with significant clinical significance 4. Women of child-bearing potential should have negative results of serum or urine pregnancy test. Women must use adequate birth control in the duration of study participation. 5. Other serious physical or mental disorders or laboratory abnormalities that may increase the risk when in this study or interfere with the results of the study, and patients whom the researchers believe are not suitable for this study.

Study Design


Intervention

Drug:
Drug: Anlotinib
Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
Drug: Carboplatin/Paclitaxel
Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wenjun Cheng

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) Progression Free Survival (PFS) is defined as the time from the initial treatment to disease progression (defined by RECIST 1.1) or death of any cause Through study completion, an average of 1-2 year
Secondary Overall Response Rate (ORR) ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by RECIST1.1 Through study completion, an average of 1 year
Secondary Disease Control Rate (DCR) Disease control rate is defined as the proportion of participants achieving complete response (CR), partial response (PR) or stable disease (SD) according to RECIST1.1. Through study completion, an average of 1 year
Secondary Overall survival (OS) Overall survival (OS) is defined as time from randomisation to the first occurrence of death from any cause [ Time Frame: From date of treatment beginning until the date of death from any cause Through study completion, an average of 1 year
Secondary Adverse events (AE) Number of participants with treatment-related adverse events as assessed by CTCAE 5.0 To further describe safety and assess toxicities encountered with the use of the proposed treatment regimen in participants Through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Completed NCT02569983 - The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
Withdrawn NCT02243059 - Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Phase 4
Terminated NCT02055690 - PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer Phase 1/Phase 2
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00415181 - Pharmacogenomics of Paclitaxel in Ovarian Cancer N/A
Recruiting NCT01789229 - Establishment of a Tumor Bank for Tissue Samples
Completed NCT00772863 - Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer Phase 2
Completed NCT00069160 - Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer Phase 2
Completed NCT00046800 - Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer Phase 2
Completed NCT00035100 - EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Phase 2
Terminated NCT00034372 - Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma Phase 2
Completed NCT00001272 - A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Completed NCT02227654 - Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors N/A
Not yet recruiting NCT04055038 - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Phase 2/Phase 3